← 홈

Antibody · 림프종

169개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 169개
AntibodystaleInstitute of Hematology & Blood…Phase 2

Zanubrutinib, bendamustine, rituximab (Zanubrutinib, bendamustine, rituximab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystalePeking UniversityPhase 2

Zanubrutinib, high-dose methotrexate (HD-MTX, Zanubrutinib, high-dose methotrexate, Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab)

Secondary Central Nervous System Lymphoma · Secondary Central Nervous System Lymphom

#SecondaryCentralNervousSystemLym#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleThe First Affiliated Hospital w…Phase 2

Zebetuzumab (Zebetuzumab)

Marginal Zone Lymphoma(MZL) · Marginal Zone Lymphoma(MZL)

#MarginalZoneLymphomaMZL#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleOu Bai, MDPhase 2

Zuberitamab-CHOP+orelabrutinib (Zuberitamab-CHOP+orelabrutinib)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleM.D. Anderson Cancer CenterPhase 2

^111 In Ibritumomab Tiuxetan (^111 In Ibritumomab Tiuxetan)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 0.8%임상시험 1상태 DISCONTINUED
AntibodystaleNational Cancer Institute (NCI)Phase 2

apolizumab (apolizumab)

Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleSeoul National University Hospi…Phase 2

bendamustine plus rituximab (bendamustine plus rituximab)

Marginal Zone B-cell Lymphoma · Marginal Zone B-cell Lymphoma

#MarginalZoneB-cellLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 81.8%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

bevacizumab, Rituximab (bevacizumab, Rituximab)

Non-Hodgkin's Lymphoma; B-cell Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 93.8%임상시험 1상태 DISCONTINUED
AntibodystaleAmgenPhase 1

blinatumomab and auto-HSCT "sandwich " strategy (blinatumomab and auto-HSCT "sandwich " strategy)

B-cell Acute Lymphoblastic Leukemia · B-cell Acute Lymphoblastic Leukemia

#B-cellAcuteLymphoblasticLeukemia#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleSingapore General HospitalPhase 1

bortezomib, rituximab, ifosphamide, etoposide, carboplatin (bortezomib, rituximab, ifosphamide, etoposide, carboplatin)

Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleCTI BioPharmaPhase 3

fludarabine and rituximab (fludarabine and rituximab)

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleCTI BioPharmaPhase 3

fludarabine, rituximab, pixantrone (fludarabine, rituximab, pixantrone)

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleSun Yat-sen UniversityPhase 2

gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab (gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab)

Lymphoma, Large B-Cell, Diffuse · Lymphoma, Large B-Cell, Diffuse

#LymphomaLargeB-CellDiffuse#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleWeill Medical College of Cornel…Phase 2

mesna, cisplatin, etoposide, rituximab (mesna, cisplatin, etoposide, rituximab)

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 83%임상시험 1상태 ACTIVE
AntibodystaleBeth ChristianPhase 2

milatuzumab (milatuzumab)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 24%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

RO5072759 (obinutuzumab, obinutuzumab (RO5072759))

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleThe First Affiliated Hospital w…Phase 2

penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin (penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin)

Lymphoma, Large B-Cell, Diffuse; Neoplasms by Histologic Type · Lymphoma, Large B-Cell, Diffuse

#LymphomaLargeB-CellDiffuse#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleCTI BioPharmaPhase 3

pixantrone, cyclophosphamide, vincristine, rituximab, prednisone (pixantrone, cyclophosphamide, vincristine, rituximab, prednisone)

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase3#항체#면역항체+4
효능 ORR 12%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim (rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim)

Hodgkin's Disease; Lymphoma · Hodgkin's Disease

#HodgkinsDisease#Antibody#Phase2#항체#면역항체+3
효능 ORR 32%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone (rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING

8 / 9 페이지

← 이전다음 →